{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:54:14Z","timestamp":1776401654047,"version":"3.51.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173865, 82304569"],"award-info":[{"award-number":["82173865, 82304569"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023B1515120056, 2024A1515011289"],"award-info":[{"award-number":["2023B1515120056, 2024A1515011289"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"crossref","award":["2024B01J1277"],"award-info":[{"award-number":["2024B01J1277"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04260-1","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:54:13Z","timestamp":1773215653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of VP30-targeted nanoparticles using DPS4 fusion peptides for the inhibition of Ebola virus"],"prefix":"10.1186","volume":"24","author":[{"given":"Fang","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peixuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinpin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanxian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"4260_CR1","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1016\/j.apsb.2022.05.023","volume":"12","author":"D Yi","year":"2022","unstructured":"Yi D, Li Q, Wang H, Lv K, Ma L, Wang Y, Wang J, Zhang Y, Liu M, Li X, et al. Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein. Acta Pharm Sin B. 2022;12:4378\u201389.","journal-title":"Acta Pharm Sin B"},{"key":"4260_CR2","doi-asserted-by":"crossref","unstructured":"Jacob ST, Crozier I, Fischer WA 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH. Ebola virus disease. Nat Rev Dis Primers. 2020;6:13.","DOI":"10.1038\/s41572-020-0147-3"},{"key":"4260_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/path.4456","volume":"235","author":"RB Martines","year":"2015","unstructured":"Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2015;235:153\u201374.","journal-title":"J Pathol"},{"key":"4260_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","volume":"12","author":"L Baseler","year":"2017","unstructured":"Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The Pathogenesis of Ebola Virus Disease. Annu Rev Pathol. 2017;12:387\u2013418.","journal-title":"Annu Rev Pathol"},{"key":"4260_CR5","doi-asserted-by":"publisher","first-page":"2392651","DOI":"10.1080\/22221751.2024.2392651","volume":"13","author":"W Li","year":"2024","unstructured":"Li W, Yang W, Liu X, Zhou W, Wang S, Wang Z, Zhao Y, Feng N, Wang T, Wu M, et al. Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model. Emerg Microbes Infect. 2024;13:2392651.","journal-title":"Emerg Microbes Infect"},{"key":"4260_CR6","unstructured":"Ebola haemorrhagic fever in Zaire. 1976. Bull World Health Organ 1978, 56:271\u2013293."},{"key":"4260_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nature19790","volume":"538","author":"EC Holmes","year":"2016","unstructured":"Holmes EC, Dudas G, Rambaut A, Andersen KG. The evolution of Ebola virus: Insights from the 2013\u20132016 epidemic. Nature. 2016;538:193\u2013200.","journal-title":"Nature"},{"key":"4260_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev-virology-092818-015708","volume":"6","author":"W Furuyama","year":"2019","unstructured":"Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019;6:435\u201358.","journal-title":"Annu Rev Virol"},{"key":"4260_CR9","doi-asserted-by":"publisher","first-page":"e28344","DOI":"10.1002\/jmv.28344","volume":"95","author":"F Branda","year":"2023","unstructured":"Branda F, Maruotti A. 2022 Uganda Ebola outbreak: Early descriptions and open data. J Med Virol. 2023;95:e28344.","journal-title":"J Med Virol"},{"key":"4260_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/14787210.2018.1413937","volume":"16","author":"M Keshtkar-Jahromi","year":"2018","unstructured":"Keshtkar-Jahromi M, Martins KAO, Cardile AP, Reisler RB, Christopher GW, Bavari S. Treatment-focused Ebola trials, supportive care and future of filovirus care. Expert Rev Anti Infect Ther. 2018;16:67\u201376.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4260_CR11","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1038\/s41467-025-59168-5","volume":"16","author":"AN Prasad","year":"2025","unstructured":"Prasad AN, Woolsey C, Borisevich V, Agans KN, Deer DJ, Geisbert JB, Harrison MB, Dobias NS, Fenton KA, Cross RW, Geisbert TW. Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus. Nat Commun. 2025;16:3824.","journal-title":"Nat Commun"},{"key":"4260_CR12","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"RT Davey Jr","year":"2016","unstructured":"Davey RT Jr., Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016;375:1448\u201356.","journal-title":"N Engl J Med"},{"key":"4260_CR13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/med.21355","volume":"35","author":"Z Janeba","year":"2015","unstructured":"Janeba Z. Development of Small-Molecule Antivirals for Ebola. Med Res Rev. 2015;35:1175\u201394.","journal-title":"Med Res Rev"},{"key":"4260_CR14","doi-asserted-by":"publisher","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","volume":"13","author":"D Sissoko","year":"2016","unstructured":"Sissoko D, Laouenan C, Folkesson E, M\u2019Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016;13:e1001967.","journal-title":"PLoS Med"},{"key":"4260_CR15","doi-asserted-by":"publisher","first-page":"e0162199","DOI":"10.1371\/journal.pone.0162199","volume":"11","author":"J Dunning","year":"2016","unstructured":"Dunning J, Kennedy SB, Antierens A, Whitehead J, Ciglenecki I, Carson G, Kanapathipillai R, Castle L, Howell-Jones R, Pardinaz-Solis R, et al. Experimental Treatment of Ebola Virus Disease with Brincidofovir. PLoS ONE. 2016;11:e0162199.","journal-title":"PLoS ONE"},{"key":"4260_CR16","doi-asserted-by":"publisher","first-page":"e0111721","DOI":"10.1128\/AAC.01117-21","volume":"65","author":"VC Yan","year":"2021","unstructured":"Yan VC, Muller FL. Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. Antimicrob Agents Chemother. 2021;65:e0111721.","journal-title":"Antimicrob Agents Chemother"},{"key":"4260_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41401-023-01055-0","volume":"44","author":"YH Ma","year":"2023","unstructured":"Ma YH, Hong X, Wu F, Xu XF, Li R, Zhong J, Zhou YQ, Liu SW, Zhan J, Xu W. Inhibiting the transcription and replication of Ebola viruses by disrupting the nucleoprotein and VP30 protein interaction with small molecules. Acta Pharmacol Sin. 2023;44:1487\u201399.","journal-title":"Acta Pharmacol Sin"},{"key":"4260_CR18","doi-asserted-by":"publisher","first-page":"106074","DOI":"10.1016\/j.antiviral.2024.106074","volume":"234","author":"C Peng","year":"2025","unstructured":"Peng C, Wu F, Ma Y, Liu G, Huang Y, Tong R, Xu W. Ginkgolic acid inhibits Ebola virus transcription and replication by disrupting the interaction between nucleoprotein and VP30 protein. Antiviral Res. 2025;234:106074.","journal-title":"Antiviral Res"},{"key":"4260_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2174\/0127724344267452231206061944","volume":"19","author":"M Soni","year":"2024","unstructured":"Soni M, Tulsian K, Barot P, Vyas VK. Recent Advances in Therapeutic Approaches Against Ebola Virus Infection. Recent Adv Antiinfect Drug Discov. 2024;19:276\u201399.","journal-title":"Recent Adv Antiinfect Drug Discov"},{"key":"4260_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coph.2021.06.010","volume":"60","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Saha A, Samanta S, Saha RP. Genome structure and genetic diversity in the Ebola virus. Curr Opin Pharmacol. 2021;60:83\u201390.","journal-title":"Curr Opin Pharmacol"},{"key":"4260_CR21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/s41564-024-01703-z","volume":"9","author":"BS Bodmer","year":"2024","unstructured":"Bodmer BS, Hoenen T, Wendt L. Molecular insights into the Ebola virus life cycle. Nat Microbiol. 2024;9:1417\u201326.","journal-title":"Nat Microbiol"},{"key":"4260_CR22","doi-asserted-by":"publisher","first-page":"8967","DOI":"10.1128\/JVI.02523-06","volume":"81","author":"SP John","year":"2007","unstructured":"John SP, Wang T, Steffen S, Longhi S, Schmaljohn CS, Jonsson CB. Ebola virus VP30 is an RNA binding protein. J Virol. 2007;81:8967\u201376.","journal-title":"J Virol"},{"key":"4260_CR23","doi-asserted-by":"publisher","first-page":"15576","DOI":"10.1038\/ncomms15576","volume":"8","author":"W Xu","year":"2017","unstructured":"Xu W, Luthra P, Wu C, Batra J, Leung DW, Basler CF, Amarasinghe GK. Ebola virus VP30 and nucleoprotein interactions modulate viral RNA synthesis. Nat Commun. 2017;8:15576.","journal-title":"Nat Commun"},{"key":"4260_CR24","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1016\/j.jmb.2019.06.029","volume":"431","author":"AJ Hume","year":"2019","unstructured":"Hume AJ, M\u00fchlberger E. Distinct Genome Replication and Transcription Strategies within the Growing Filovirus Family. J Mol Biol. 2019;431:4290\u2013320.","journal-title":"J Mol Biol"},{"key":"4260_CR25","doi-asserted-by":"publisher","first-page":"e1005937","DOI":"10.1371\/journal.ppat.1005937","volume":"12","author":"RN Kirchdoerfer","year":"2016","unstructured":"Kirchdoerfer RN, Moyer CL, Abelson DM, Saphire EO. The Ebola Virus VP30-NP Interaction Is a Regulator of Viral RNA Synthesis. PLoS Pathog. 2016;12:e1005937.","journal-title":"PLoS Pathog"},{"key":"4260_CR26","doi-asserted-by":"publisher","first-page":"113892","DOI":"10.1016\/j.addr.2021.113892","volume":"176","author":"B Zhang","year":"2021","unstructured":"Zhang B, Tang G, He J, Yan X, Fan K. Ferritin nanocage: A promising and designable multi-module platform for constructing dynamic nanoassembly-based drug nanocarrier. Adv Drug Deliv Rev. 2021;176:113892.","journal-title":"Adv Drug Deliv Rev"},{"key":"4260_CR27","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1172\/JCI127511","volume":"129","author":"M Uchida","year":"2019","unstructured":"Uchida M, Maier B, Waghwani HK, Selivanovitch E, Pay SL, Avera J, Yun E, Sandoval RM, Molitoris BA, Zollman A, et al. The archaeal Dps nanocage targets kidney proximal tubules via glomerular filtration. J Clin Invest. 2019;129:3941\u201351.","journal-title":"J Clin Invest"},{"key":"4260_CR28","doi-asserted-by":"publisher","first-page":"130067","DOI":"10.1016\/j.bbagen.2021.130067","volume":"1866","author":"AI Kuruppu","year":"2022","unstructured":"Kuruppu AI, Turyanska L, Bradshaw TD, Manickam S, Galhena BP, Paranagama P, De Silva R. Apoferritin and Dps as drug delivery vehicles: Some selected examples in oncology. Biochim Biophys Acta Gen Subj. 2022;1866:130067.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"4260_CR29","doi-asserted-by":"publisher","first-page":"e2119467119","DOI":"10.1073\/pnas.2119467119","volume":"119","author":"K Yang","year":"2022","unstructured":"Yang K, Wang C, White KI, Pfuetzner RA, Esquivies L, Brunger AT. Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle. Proc Natl Acad Sci U S A. 2022;119:e2119467119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4260_CR30","doi-asserted-by":"publisher","first-page":"e0003622","DOI":"10.1128\/jb.00036-22","volume":"204","author":"K Orban","year":"2022","unstructured":"Orban K, Finkel SE. Dps Is a Universally Conserved Dual-Action DNA-Binding and Ferritin Protein. J Bacteriol. 2022;204:e0003622.","journal-title":"J Bacteriol"},{"key":"4260_CR31","doi-asserted-by":"publisher","first-page":"10551","DOI":"10.1073\/pnas.0501497102","volume":"102","author":"B Wiedenheft","year":"2005","unstructured":"Wiedenheft B, Mosolf J, Willits D, Yeager M, Dryden KA, Young M, Douglas T. An archaeal antioxidant: characterization of a Dps-like protein from Sulfolobus solfataricus. Proc Natl Acad Sci U S A. 2005;102:10551\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4260_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/76744","volume":"7","author":"T Selzer","year":"2000","unstructured":"Selzer T, Albeck S, Schreiber G. Rational design of faster associating and tighter binding protein complexes. Nat Struct Biol. 2000;7:537\u201341.","journal-title":"Nat Struct Biol"},{"key":"4260_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2017.08.005","volume":"146","author":"EV Nelson","year":"2017","unstructured":"Nelson EV, Pacheco JR, Hume AJ, Cressey TN, Deflub\u00e9 LR, Ruedas JB, Connor JH, Ebihara H, M\u00fchlberger E. An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening. Antiviral Res. 2017;146:21\u20137.","journal-title":"Antiviral Res"},{"key":"4260_CR34","doi-asserted-by":"publisher","first-page":"105161","DOI":"10.1016\/j.antiviral.2021.105161","volume":"194","author":"M Gong","year":"2021","unstructured":"Gong M, Yang Y, Huang Y, Gan T, Wu Y, Gao H, Li Q, Nie J, Huang W, Wang Y, et al. Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. Antiviral Res. 2021;194:105161.","journal-title":"Antiviral Res"},{"key":"4260_CR35","first-page":"529","volume":"11","author":"H Kong","year":"2021","unstructured":"Kong H, Li M, Xu Q, Zhou H, Yu F, Wang Q. Implementation of level-2 biosafety for a macromolecular crystallography beamline at SSRF. Am J Nucl Med Mol Imaging. 2021;11:529\u201336.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"4260_CR36","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1107\/S1600576723007057","volume":"56","author":"W Brehm","year":"2023","unstructured":"Brehm W, Trivi\u00f1o J, Krahn JM, Us\u00f3n I, Diederichs K. XDSGUI: a graphical user interface for XDS, SHELX and ARCIMBOLDO. J Appl Crystallogr. 2023;56:1585\u201394.","journal-title":"J Appl Crystallogr"},{"key":"4260_CR37","doi-asserted-by":"crossref","unstructured":"Rosignoli S, Paiardini A. Boosting the Full Potential of PyMOL with Structural Biology Plugins. Biomolecules. 2022;12:1764.","DOI":"10.3390\/biom12121764"},{"key":"4260_CR38","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1021\/acs.jcim.4c02158","volume":"65","author":"V Talagayev","year":"2025","unstructured":"Talagayev V, Chen Y, Doering NP, Obendorf L, Denzinger K, Puls K, Lam K, Liu S, Wolf CA, Noonan T, et al. OpenMMDL - Simplifying the Complex: Building, Simulating, and Analyzing Protein-Ligand Systems in OpenMM. J Chem Inf Model. 2025;65:1967\u201378.","journal-title":"J Chem Inf Model"},{"key":"4260_CR39","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1006\/jmbi.2000.4404","volume":"306","author":"RR Gabdoulline","year":"2001","unstructured":"Gabdoulline RR, Wade RC. Protein-protein association: investigation of factors influencing association rates by brownian dynamics simulations. J Mol Biol. 2001;306:1139\u201355.","journal-title":"J Mol Biol"},{"key":"4260_CR40","doi-asserted-by":"publisher","first-page":"9223","DOI":"10.1073\/pnas.0401160101","volume":"101","author":"C Kiel","year":"2004","unstructured":"Kiel C, Selzer T, Shaul Y, Schreiber G, Herrmann C. Electrostatically optimized Ras-binding Ral guanine dissociation stimulator mutants increase the rate of association by stabilizing the encounter complex. Proc Natl Acad Sci U S A. 2004;101:9223\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4260_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.phrs.2016.03.002","volume":"107","author":"M Truffi","year":"2016","unstructured":"Truffi M, Fiandra L, Sorrentino L, Monieri M, Corsi F, Mazzucchelli S. Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol Res. 2016;107:57\u201365.","journal-title":"Pharmacol Res"},{"key":"4260_CR42","doi-asserted-by":"crossref","unstructured":"Tao W, Gan T, Guo M, Xu Y, Zhong J. Novel Stable Ebola Virus Minigenome Replicon Reveals Remarkable Stability of the Viral Genome. J Virol. 2017;91:e01316-17.","DOI":"10.1128\/JVI.01316-17"},{"key":"4260_CR43","doi-asserted-by":"publisher","first-page":"eadq2496","DOI":"10.1126\/scitranslmed.adq2496","volume":"17","author":"T Mdluli","year":"2025","unstructured":"Mdluli T, Wollen-Roberts S, Merbah M, Beckman B, Li Y, Alrubayyi A, Curtis DJ, Shubin Z, Barrera MD, Boeckelman J, et al. Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses. Sci Transl Med. 2025;17:eadq2496.","journal-title":"Sci Transl Med"},{"key":"4260_CR44","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1473-3099(15)00222-4","volume":"15","author":"JE Ledgerwood","year":"2015","unstructured":"Ledgerwood JE. Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort. Lancet Infect Dis. 2015;15:1117\u20139.","journal-title":"Lancet Infect Dis"},{"key":"4260_CR45","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","volume":"391","author":"JJ Muyembe","year":"2024","unstructured":"Muyembe JJ, Pan H, Peto R, Diallo A, Tour\u00e9 A, Mbala-Kingebene P, Bateyi Mustafa SH, Tambwe N, Mulangu S, Ahuka-Mundeke S, et al. Ebola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination. N Engl J Med. 2024;391:2327\u201336.","journal-title":"N Engl J Med"},{"key":"4260_CR46","doi-asserted-by":"publisher","first-page":"e0108322","DOI":"10.1128\/jvi.01083-22","volume":"96","author":"Y Takamatsu","year":"2022","unstructured":"Takamatsu Y, Yoshikawa T, Kurosu T, Fukushi S, Nagata N, Shimojima M, Ebihara H, Saijo M, Noda T. Role of VP30 Phosphorylation in Ebola Virus Nucleocapsid Assembly and Transport. J Virol. 2022;96:e0108322.","journal-title":"J Virol"},{"key":"4260_CR47","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1128\/JVI.03257-15","volume":"90","author":"N Biedenkopf","year":"2016","unstructured":"Biedenkopf N, Lier C, Becker S. Dynamic Phosphorylation of VP30 Is Essential for Ebola Virus Life Cycle. J Virol. 2016;90:4914\u201325.","journal-title":"J Virol"},{"key":"4260_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1743-8977-10-24","volume":"10","author":"C Bussy","year":"2013","unstructured":"Bussy C, Paineau E, Cambedouzou J, Brun N, Mory C, Fayard B, Salom\u00e9 M, Pinault M, Huard M, Belade E, et al. Intracellular fate of carbon nanotubes inside murine macrophages: pH-dependent detachment of iron catalyst nanoparticles. Part Fibre Toxicol. 2013;10:24.","journal-title":"Part Fibre Toxicol"},{"key":"4260_CR49","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1073\/pnas.0913192107","volume":"107","author":"L Li","year":"2010","unstructured":"Li L, Fang CJ, Ryan JC, Niemi EC, Lebr\u00f3n JA, Bj\u00f6rkman PJ, Arase H, Torti FM, Torti SV, Nakamura MC, Seaman WE. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A. 2010;107:3505\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4260_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-60761-670-2_2","volume":"627","author":"P Schuck","year":"2010","unstructured":"Schuck P, Zhao H. The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing. Methods Mol Biol. 2010;627:15\u201354.","journal-title":"Methods Mol Biol"},{"key":"4260_CR51","doi-asserted-by":"publisher","first-page":"066010","DOI":"10.1088\/1478-3975\/13\/6\/066010","volume":"13","author":"J Carroll","year":"2016","unstructured":"Carroll J, Raum M, Forsten-Williams K, T\u00e4uber UC. Ligand-receptor binding kinetics in surface plasmon resonance cells: a Monte Carlo analysis. Phys Biol. 2016;13:066010.","journal-title":"Phys Biol"},{"key":"4260_CR52","doi-asserted-by":"publisher","first-page":"6451","DOI":"10.1039\/C6SM00995F","volume":"12","author":"W Wang","year":"2016","unstructured":"Wang W, Voigt A, Sundmacher K. The interaction of protein-coated bionanoparticles and surface receptors reevaluated: how important is the number of bonds? Soft Matter. 2016;12:6451\u201362.","journal-title":"Soft Matter"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04260-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04260-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04260-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:15:20Z","timestamp":1776399320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04260-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4260"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04260-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"371"}}